Table 1.
Clinical characteristics and variables in men with prostate fibrosis before the treatment (group A) or placebo (group B)
| Group A (n=32) | Group B (=32) | P value | |
|---|---|---|---|
| Age (years) | 35 (30-49) | 35 (30-49) | ns |
| Prostate volume (ml) | 28.4 (22-30) | 27.1 (22-30) | ns |
| PSA (ng/mL) | 2.0 (1.3-2.5) | 2.0 (1.4-2.4) | ns |
| PVR (ml) | 49 (5-70) | 45 (5-65) | ns |
| Total IPSS score | 19.5 (9-24) | 19.0 (9-24) | ns |
| No. of patients with severe symptoms (overall score >20) (%) | 11 (34.3%) | 10 (31.2%) | ns |
| Total NIH-CPSI score | 17.5 (14-22) | 18.0 (14-23) | ns |
| Periurethral prostatic calcification (diameter >3 mm) at TRUS | |||
| Mean number (range) | 3 (2-4) | 3 (2-4) | ns |
| Mean diameter (mm) (range) | 7 (4-12) | 6.5 (4-11) | ns |
| WBC on EPS after prostate massage or VB3 (counts/hpf) | 11 (8-16) | 10 (8-15) | ns |
Values are presented as mean±standard deviation. ns = not significant difference;
Abbreviations: PSA: serum prostate specific antigen; PVR: postvoid residual urine, IPSS: International Prostate Symptom Score. IPSS: international prostate symptom score; hpf: high power field; NIH-CPSI: National Institutes of Health Chronic Prostatitis Symptom Index; TRUS: Transrectal ultrasonography; EPS: expressed prostatic secretion; WBC: white blood cell.